Sign In

Login

Password

Forgot Password ? Sign Up

Ridinilazole (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ridinilazole" in English language version.

refsWebsite
Global rank English rank
7nih.gov
4th place
4th place
5doi.org
2nd place
2nd place
2semanticscholar.org
11th place
8th place
1clinicaltrials.gov
5,225th place
4,062nd place
1fda.gov
447th place
338th place
1phe.gov
low place
low place

clinicaltrials.gov

  • Clinical trial number NCT03595553 for "Ri-CoDIFy 1: Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection" at ClinicalTrials.gov

doi.org

  • Cho JC, Crotty MP, Pardo J (March 2019). "Clostridium difficile infection". Annals of Gastroenterology. 32 (2): 134–140. doi:10.20524/aog.2018.0336. PMC 6394264. PMID 30837785.
  • Carlson TJ, Endres BT, Bassères E, Gonzales-Luna AJ, Garey KW (April 2019). "Ridinilazole for the treatment of Clostridioides difficile infection". Expert Opinion on Investigational Drugs. 28 (4): 303–310. doi:10.1080/13543784.2019.1582640. PMID 30767587. S2CID 73422150.
  • Bassères E, Endres BT, Dotson KM, Alam MJ, Garey KW (January 2017). "Novel antibiotics in development to treat Clostridium difficile infection". Current Opinion in Gastroenterology. 33 (1): 1–7. doi:10.1097/MOG.0000000000000332. PMID 28134686. S2CID 32454489. These tables highlight the increased drug development directed towards CDI due to the rise in prevalence of infections and to attempt to reduce the number of recurrent infections.
  • Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH (August 2016). "Ridinilazole: a novel therapy for Clostridium difficile infection". International Journal of Antimicrobial Agents. 48 (2): 137–43. doi:10.1016/j.ijantimicag.2016.04.026. PMID 27283730. there exists a significant unmet and increasing medical need for new therapies to treat CDI, specifically those that can reduce the rate of disease recurrence.
  • Collins DA, Riley TV (September 2022). "Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile". Letters in Applied Microbiology. 75 (3): 526–536. doi:10.1111/lam.13664. PMC 9541751. PMID 35119124.

fda.gov

  • "Fast Track". U.S. Food and Drug Administration. 2018-11-03.

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Cho JC, Crotty MP, Pardo J (March 2019). "Clostridium difficile infection". Annals of Gastroenterology. 32 (2): 134–140. doi:10.20524/aog.2018.0336. PMC 6394264. PMID 30837785.
  • Carlson TJ, Endres BT, Bassères E, Gonzales-Luna AJ, Garey KW (April 2019). "Ridinilazole for the treatment of Clostridioides difficile infection". Expert Opinion on Investigational Drugs. 28 (4): 303–310. doi:10.1080/13543784.2019.1582640. PMID 30767587. S2CID 73422150.
  • Bassères E, Endres BT, Dotson KM, Alam MJ, Garey KW (January 2017). "Novel antibiotics in development to treat Clostridium difficile infection". Current Opinion in Gastroenterology. 33 (1): 1–7. doi:10.1097/MOG.0000000000000332. PMID 28134686. S2CID 32454489. These tables highlight the increased drug development directed towards CDI due to the rise in prevalence of infections and to attempt to reduce the number of recurrent infections.
  • Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH (August 2016). "Ridinilazole: a novel therapy for Clostridium difficile infection". International Journal of Antimicrobial Agents. 48 (2): 137–43. doi:10.1016/j.ijantimicag.2016.04.026. PMID 27283730. there exists a significant unmet and increasing medical need for new therapies to treat CDI, specifically those that can reduce the rate of disease recurrence.
  • Collins DA, Riley TV (September 2022). "Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile". Letters in Applied Microbiology. 75 (3): 526–536. doi:10.1111/lam.13664. PMC 9541751. PMID 35119124.

ncbi.nlm.nih.gov

  • Cho JC, Crotty MP, Pardo J (March 2019). "Clostridium difficile infection". Annals of Gastroenterology. 32 (2): 134–140. doi:10.20524/aog.2018.0336. PMC 6394264. PMID 30837785.
  • Collins DA, Riley TV (September 2022). "Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile". Letters in Applied Microbiology. 75 (3): 526–536. doi:10.1111/lam.13664. PMC 9541751. PMID 35119124.

phe.gov

semanticscholar.org

api.semanticscholar.org